22 diciembre 2013

Yondelis + DLP Como Tratamiento ROC de 2ª Línea Permite Tratar a las Pacientes que Aún no se han Recuperado de las Toxicidades de los Platinos ... Mejora la Supervivencia Global ... Tiene el Potencial de Restablecer la Sensibilidad al Platino ... y Permite una 3ª Linea de Tratamiento con Platinos .

Studies from University of Milan Have Provided New Data on Ovarian Cancer . 2013 DEC 18 (NewsRx).

By a News Reporter-Staff News Editor at Biotech Week .


Investigators publish new report on Oncology. According to news reporting originating in Milan, Italy, by NewsRx editors, the research stated, "Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death."

The news reporters obtained a quote from the research from the University of Milan, "Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity."

According to the news reporters, the research concluded: "In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen."